Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)

Makoto Nishio, Shunichi Sugawara, Shinji Atagi, Hiroaki Akamatsu, Hiroshi Sakai, Isamu Okamoto, Koichi Takayama, Hidetoshi Hayashi, Yuki Nakagawa, Tomohisa Kawakami

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抜粋

Atezolizumab is effective and well-tolerated in patients with extensive-stage small-cell lung cancer (ES-SCLC). We examined atezolizumab's efficacy and safety in 42 Japanese patients with ES-SCLC via a subanalysis of the phase I/III IMpower133 trial. Addition of atezolizumab to chemotherapy improved overall survival and was generally well-tolerated, thus offering a potentially new treatment for Japanese patients with ES-SCLC.

元の言語英語
ページ(範囲)469-476.e1
ジャーナルClinical Lung Cancer
20
発行部数6
DOI
出版物ステータス出版済み - 11 2019

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

これを引用